According to the Synergy Research Group report, the most active CRO in the region were OCT, Quintiles, PSI, Synergy Research Group and IPHARMA. OCT has been working with the largest number of patients during this period. AbbVie tops the list of the leaders among foreign pharmaceutical companies, which initiated clinical trials in 3Q, while Biocad and Severnaya Zvezda were named the most active among Russian companies.

In 2016, OCT obtained approvals for the conduct of 12 new clinical trials and became one of the leading CROs in the region. Thus, even without all the projects where sponsors made regulatory submissions independently. To date, OCT has completed a total of 250 clinical projects.